Abstract:Background: Risperidone ISM® is a newly developed long-acting injectable (LAI) treatment for schizophrenia in adults. In the absence of head-to-head comparisons with other similar antipsychotics, the objective of this study was to generate indirect evidence of some aspects of the safety and tolerability of Risperidone ISM compared to other LAI antipsychotics for treatment of patients with schizophrenia in the maintenance treatment setting. Methods: A literature review was conducted systematically to identify maintenance treatment studies reporting safety and tolerability outcomes for LAI antipsychotic therapies. Following an assessment of between-trial heterogeneity, a matching-adjusted indirect comparison (MAIC) was performed to account for between-trial imbalances in patient characteristics and to generate comparative evidence for safety and tolerability endpoints. Results: The analysis showed that incidence of extrapyramidal symptoms (EPS) was found to be numerically, but not statistically significantly, lower in patients receiving Risperidone ISM than in those receiving Paliperidone palmitate (PP) (OR [95% CI] 0.63 [0.29, 1.38], p = 0.253) and statistically significantly lower than with Aripiprazole monohydrate once-monthly (AOM) (OR [95% CI] 0.25 [0.12, 0.53], p < 0.001). Use of anticholinergic agents for the alleviation of EPS was also shown to be significantly lower in Risperidone ISM patients than in those receiving PP (OR [95% CI] 0.29 [0.10, 0.83], p = 0.021) or AOM (OR [95% CI] 0.01 [0.003, 0.06], p < 0.001), suggesting a superior tolerability profile for clinically relevant EPS. Results from the sensitivity analyses comparing stabilized and stable patients receiving Risperidone ISM to those receiving AOM yielded similarly favorable conclusions in line with the base case analyses. Conclusions: This MAIC is consistent with the safety and tolerability results obtained during the PRISMA-3 clinical trial in the long-term treatment of schizophrenia and suggests a favorable safety and tolerability profile in terms of EPS incidence and anticholinergic agent use, relative to other antipsychotic therapies used for treatment of patients with schizophrenia in the maintenance setting.

Efficacy and Safety of Paliperidone Palmitate or Long-acting Injectable Risperidone in Patients with Schizophrenia

A double blinded multicenter clinical trial for evaluating the efficacy and safety of aripiprazole and risperidone in the treatment of schizophrenia

Efficacy and Safety of Long-Acting Injectable Risperidone in Patients with Schizophrenia

Efficacy and Safety of Long-Acting Risperidone on Early Onset Schizophrenia in Adolescent Patients

The Efficacy and Safety of Risperidone Long-Acting Injectable for the Treatment of Schizophrenia

Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia A Randomized, Double-Blind, Multicenter Study

A clinical observation of long-acting injectable risperidone in patients with schizophrenia

Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia

A clinical controlled study on schizophrenia treated with paliperidone-ER and risperidone

A Randomized, 13-Week Study Assessing the Efficacy and Metabolic Effects of Paliperidone Palmitate Injection and Olanzapine in First-Episode Schizophrenia Patients

Clinical study on the efficacy of paliperidone extended-release tablets in the treatment of schizophrenia outpatients and its effect on social function

A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.

A Comparative Study of Aripiprazole Versus Risperdal in Patients with Schizophrenia

Clinical outcomes of paliperidone long-acting injection in patients with schizophrenia: a 1-year retrospective cohort study

Double-blind,double-dummy and randomized controlled study of aripiprazole in the treatment of acute schizophrenia

Open Observation and Control Study of the Efficacy and Safety of Paliperi-done Extended-release Tablets and Risperidone Tablets in the Treatment of First-episode Schizophrenia

Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study.

A Control Study on Aripiprazole and Risperidone in the Treatment of Schizophrenia.

Comparative Efficacy of First and Second Generation long-acting injectable antipsychotic upon schizophrenic patients: a systematic review and network metaanalysis.

Improving Efficacy of Risperidone Long-Acting Injection on Cognition Functions in Patients with Schizophrenia